News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 12 - 24

First Domestic pVAD Approved by NMPA for Marketing | Fenix Investment Update

Recently, the NMPA announced the approval of Core Medical Technology Co., Ltd.'s percutaneous left ventricular assist device and percutaneous left ventricular assist catheter pump kit for marketing.This system utilizes miniaturized axial motor technology for short-term left ventricular assistance. It represents a domestic首创 technology, filling the technological gap in domestic percutaneous cardiac assist devices.According to research data from several professional institutions, global sales of percutaneous ventricular assist devices (essentially equivalent to pVAD) are expected to reach RM...

浏览次数：1

查看详情>>

发布时间: 2025 - 12 - 24

Azvudine Combined with PD-1 Efficacy Further Validated! Major Breakthrough in Tumor Immunotherapy

Recently, Genuine Biotech, in collaboration with the First Affiliated Hospital of Zhengzhou University and the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Sciences, published a research paper titled "Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies" in Frontiers of Medicine, systematically exploring the anti-tumor efficacy and mechanisms of Azvudine (FNC) combined with anti-PD-1 therapy.The study confirmed that Azvudine monotherapy significantly inhibits sol...

浏览次数：1

查看详情>>

发布时间: 2025 - 12 - 19

Efung Capital Named to ChinaVenture's 2025 Top 30 Best VC Institutions in GBA

Today, ChinaVenture Information released its "2025 Guangdong-Hong Kong-Macao Greater Bay Area Ranking." Efung Capital was named to ChinaVenture's 2025 Top 30 Best Venture Capital Institutions in the Greater Bay Area.This ranking surveyed nearly 200 equity investment institutions and approximately 60 guidance funds in the Greater Bay Area. Adopting a combination of quantitative and qualitative methodologies, the evaluation assessed selected institutions based on criteria including assets under management, investment activity, and exit performance. The process involved initial scre...

浏览次数：1

查看详情>>

发布时间: 2025 - 12 - 17

First Patient Dosed in U.S. Pivotal Clinical Study of Utidelone for Breast Cancer Brain Metastases

On December 15, 2025, Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd., announced the first patient dosing in its U.S. pivotal registrational clinical study (NCT06764940) evaluating Utidelone injection (UTD1), one of its core product's key overseas clinical pipelines, in combination with capecitabine for HER2-negative breast cancer brain metastases (BCBM).The study adopts a two-stage design and plans to enroll approximately 120 subjects. The primary endpoint is central nervous system objective response rate (CNS-ORR). Nearly 20 ...

浏览次数：1

查看详情>>